Curaleaf Holdings (CURLF) Current Assets (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Current Assets of $448.6 million for Q4 2025, up 3.28% year-on-year from $434.4 million in Q4 2024, and up 3.28% on a QoQ basis from $434.4 million in Q4 2024.
Curaleaf Holdings (CURLF) Current Assets (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Current Assets for 7 consecutive years, with $448.6 million the latest figure, recorded in Q4 2025.
- Quarterly Current Assets rose 3.28% year-over-year to $448.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $448.6 million (up 3.28% YoY) and the FY2025 annual result came in at $448.6 million, up 3.28% from the prior year.
- Current Assets advanced to $448.6 million in Q4 2025 per CURLF's latest filing, from $434.4 million in the prior quarter.
- Over the last five years, Current Assets for CURLF reached as high as $978.0 billion in Q1 2022 and fell as low as $418.6 million in Q4 2023.
- A 5-year average of $65.8 billion and a median of $652.4 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets soared 135828.6% — and 2023, when it tumbled 50.36%.
- Year by year, Current Assets stood at $726.6 million in 2021, then declined by 10.21% to $652.4 million in 2022, then slumped by 35.84% to $418.6 million in 2023, then advanced by 3.77% to $434.4 million in 2024, then gained by 3.28% to $448.6 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $448.6 million, $434.4 million, and $422.2 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.05 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.71 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 6.47 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 19.71 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 2.87 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 53.60 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 10.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.44 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.58 Bn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 448.62 Mn |
| Dec 31, 2024 | 434.37 Mn |
| Sep 30, 2024 | 422.22 Mn |
| Jun 30, 2024 | 426.73 Mn |
| Dec 31, 2023 | 418.60 Mn |
| Sep 30, 2023 | 483.79 Mn |
| Jun 30, 2023 | 463.43 Mn |
| Dec 31, 2022 | 652.43 Mn |
| Sep 30, 2022 | 920.77 Mn |
| Jun 30, 2022 | 933.63 Mn |
| Mar 31, 2022 | 977.98 Bn |
| Dec 31, 2021 | 726.62 Mn |
| Sep 30, 2021 | 906.51 Mn |
| Jun 30, 2021 | 805.53 Mn |
| Mar 31, 2021 | 719.48 Mn |
| Dec 31, 2020 | 417.86 Mn |
| Sep 30, 2020 | 376.87 Mn |
| Dec 31, 2019 | 149.53 Mn |